Clinical Performance of Signatera and Reveal ctDNA assays: A Systematic Review of Real-World Data Across Cancer Types

This project presents a systematic review of the currently available clinical performance data of the two leading circulating tumor DNA (ctDNA) assays: Natera’s Signatera and Guardant Health’s Reveal. Drawing on data from 25 peer-reviewed studies across 16 different cancer types, the analysis investigates real-world associations between post-treatment ctDNA presence and key clinical outcomes such as recurrence and progression-free survival (PFS).